Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 28, 2011

Perrigo’s Generic Clarinex Gets U.S. Okay

  • FDA has rubber-stamped Perrigo’s desloratadine (5 mg) tablets, a generic version of Schering-Plough’s Clarinex® tablets, for treating seasonal and perennial allergic rhinitis. Approval of the drug follows the 2008 settlement of a patent infringement lawsuit against Perrigo, relating to its filing of an ANDA containing a Paragraph IV certification.

    Under terms of the settlement the firm will be able to commercially launch the generic desloratadine product on July 1, 2012, or potentially earlier under certain circumstances. Whether the drug will be launched as a prescription or OTC product will depend on its status at the time, Perrigo states.

    Last month FDA approved Perrigo’s ANDA for guaifenesin extended-release tablets, 600 mg, as a generic version of Mucinex® tablets. Perrigo is still in litigation with Reckitt Benckiser, the NDA holder and patent owner of Mucinex.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »